Vatiquinone - CAS 1213269-98-7
Catalog number: 1213269-98-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C29H44O3
Molecular Weight:
440.67
COA:
Inquire
Targets:
Others
Description:
This active molecular has a para-benzoquinone structure and was developed for inherited mitochondrial diseases base on vitamin E. The mechanism of action of Vatiquinone involves increasing the synthesis of glutathione, optimizing metabolic control and so on. Now it is in Phase I for Gilles de la Tourette's syndrome, in Phase II for Friedreich's ataxia; Methylmalonic acidaemia; Mitochondrial disorders; Noise-induced hearing loss; Parkinson's disease; Rett syndrome Friedreich's ataxia; Methylmalonic acidaemia; Mitochondrial disorders; Noise-induced hearing loss; Parkinson's disease and Rett syndrome, in Phase III for Leigh disease.
Purity:
98%
Appearance:
Powder
Synonyms:
EPI743; EPI-743; EPI 743; alpha-Tocotrienol quinone;2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
Solubility:
Soluble in DMSO
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
inherited mitochondrial diseases
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
LNOVHERIIMJMDG-XZXLULOTSA-N
InChI:
InChI=1S/C29H44O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h12,14,16,32H,9-11,13,15,17-19H2,1-8H3/b21-14+,22-16+/t29-/m1/s1
Canonical SMILES:
CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C
Current Developer:
Edison Pharmaceuticals; Sumitomo Dainippon Pharma; University of Florida; Yale University
1.Therapies for mitochondrial diseases and current clinical trials.
El-Hattab AW;Zarante AM;Almannai M;Scaglia F Mol Genet Metab. 2017 Nov;122(3):1-9. doi: 10.1016/j.ymgme.2017.09.009. Epub 2017 Sep 18.
Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders that result from dysfunction of the mitochondrial oxidative phosphorylation due to molecular defects in genes encoding mitochondrial proteins. Despite the advances in molecular and biochemical methodologies leading to better understanding of the etiology and mechanism of these diseases, there are still no satisfactory therapies available for mitochondrial disorders. Treatment for mitochondrial diseases remains largely symptomatic and does not significantly alter the course of the disease. Based on limited number of clinical trials, several agents aiming at enhancing mitochondrial function or treating the consequences of mitochondrial dysfunction have been used. Several agents are currently being evaluated for mitochondrial diseases. Therapeutic strategies for mitochondrial diseases include the use of agents enhancing electron transfer chain function (coenzyme Q;10;, idebenone, riboflavin, dichloroacetate, and thiamine), agents acting as energy buffer (creatine), antioxidants (vitamin C, vitamin E, lipoic acid, cysteine donors, and EPI-743), amino acids restoring nitric oxide production (arginine and citrulline), cardiolipin protector (elamipretide), agents enhancing mitochondrial biogenesis (bezafibrate, epicatechin, and RTA 408), nucleotide bypass therapy, liver transplantation, and gene therapy.
2.Mitochondrial genetics and therapeutic overview of Leber's hereditary optic neuropathy.
Manickam AH;Michael MJ;Ramasamy S Indian J Ophthalmol. 2017 Nov;65(11):1087-1092. doi: 10.4103/ijo.IJO_358_17.
Leber's hereditary optic neuropathy (LHON) is a common inherited mitochondrial disorder that is characterized by the degeneration of the optic nerves, leading to vision loss. The major mutations in the mitochondrial genes ND1, ND4, and ND6 of LHON subjects are found to increase the oxidative stress experienced by the optic nerve cell, thereby leading to nerve cell damage. Accurate treatments are not available and drugs that are commercially available like Idebenone, EPI-743, and Bendavia with their antioxidant role help in reducing the oxidative stress experienced by the cell thereby preventing the progression of the disease. Genetic counseling plays an effective role in making the family members aware of the inheritance pattern of the disease. Gene therapy is an alternative for curing the disease but is still under study. This review focuses on the role of mitochondrial genes in causing LHON and therapeutics available for treating the disease. A systematic search has been adopted in various databases using the keywords "LHON," "mitochondria," "ND1," "ND4," "ND6," and "therapy" and the following review on mitochondrial genetics and therapeutics of LHON has been developed with obtained articles from 1988 to 2017.
3.Initial experience in the treatment of inherited mitochondrial disease with EPI-743.
Enns GM;Kinsman SL;Perlman SL;Spicer KM;Abdenur JE;Cohen BH;Amagata A;Barnes A;Kheifets V;Shrader WD;Thoolen M;Blankenberg F;Miller G Mol Genet Metab. 2012 Jan;105(1):91-102. doi: 10.1016/j.ymgme.2011.10.009. Epub 2011 Oct 21.
Inherited mitochondrial respiratory chain disorders are progressive, life-threatening conditions for which there are limited supportive treatment options and no approved drugs. Because of this unmet medical need, as well as the implication of mitochondrial dysfunction as a contributor to more common age-related and neurodegenerative disorders, mitochondrial diseases represent an important therapeutic target. Thirteen children and one adult with genetically-confirmed mitochondrial disease (polymerase γ deficiency, n=4; Leigh syndrome, n=4; MELAS, n=3; mtDNA deletion syndrome, n=2; Friedreich ataxia, n=1) at risk for progressing to end-of-life care within 90 days were treated with EPI-743, a novel para-benzoquinone therapeutic, in a subject controlled, open-label study. Serial measures of safety and efficacy were obtained that included biochemical, neurological, quality-of-life, and brain redox assessments using technetium-99m-hexamethylpropyleneamine oxime (HMPAO) single photon emission computed tomography (SPECT) radionuclide imaging. Twelve patients treated with EPI-743 have survived; one polymerase γ deficiency patient died after developing pneumonia and one patient with Surf-1 deficiency died after completion of the protocol.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


LY 164929
(CAS: 113573-18-5)

This active molecular is a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site.

CAS 123714-50-1 Acetyl-Calpastatin (184-210) (human)

Acetyl-Calpastatin (184-210) (human)
(CAS: 123714-50-1)

Acetyl-Calpastatin (184-210) (human) is a calpain I/II inhibitor and could increase secretion of amyoid β-protein (Aβ) 42, Aβ40 and Aβ42 ratio.

CAS 452-35-7 Ethoxzolamide

Ethoxzolamide
(CAS: 452-35-7)

Ethoxzolamide is used in the treatment of glaucoma, and is also used as a diuretic, acting as a carbonic anhydrase inhibitor.

APCP-363
(CAS: 340023-40-7)

APCP-363 a bio-active chemical.

CAS 6093-71-6 YZ9

YZ9
(CAS: 6093-71-6)

YZ9 is a PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor (IC50 = 0.183 μM). YZ9 also competitively inhibits F-6-P (Ki = 0.094 μM), and s...

CAS 1421227-52-2 WS3

WS3
(CAS: 1421227-52-2)

WS3 induces proliferation of the mouse β cell line R7T1 with EC50 of 0.074 μM.

CAS 314-13-6 Evans Blue

Evans Blue
(CAS: 314-13-6)

Evans Blue is a potent inhibitor of L-glutamate uptake into synaptic vesicles and is able to antagonize AMPA (IC50=220 nM) and kainate receptor (IC50=150 nM) me...

CAS 207727-86-4 NB-caged Tyrosine hydrochloride

NB-caged Tyrosine hydrochloride
(CAS: 207727-86-4)

NB-caged Tyrosine hydrochloride is L-Tyrosine caged with photosensitive ortho-nitrobenzyl side chain. It can release tyrosine when photolyzed.

Quick Inquiry

Verification code

Featured Items